Novo Nordisk A/S (NYSE:NVO) Shares Bought by MCF Advisors LLC

MCF Advisors LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 5,850.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 476 shares of the company’s stock after purchasing an additional 468 shares during the period. MCF Advisors LLC’s holdings in Novo Nordisk A/S were worth $49,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Clarius Group LLC increased its position in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after acquiring an additional 93 shares in the last quarter. Tradewinds Capital Management LLC increased its position in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after acquiring an additional 95 shares in the last quarter. Relyea Zuckerberg Hanson LLC increased its position in shares of Novo Nordisk A/S by 3.2% in the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after acquiring an additional 99 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in shares of Novo Nordisk A/S by 3.5% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after acquiring an additional 100 shares in the last quarter. Finally, Highlander Capital Management LLC increased its position in shares of Novo Nordisk A/S by 0.4% in the fourth quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on NVO shares. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $125.23 on Tuesday. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $561.97 billion, a PE ratio of 46.30, a price-to-earnings-growth ratio of 2.05 and a beta of 0.41. The company has a 50 day moving average price of $126.49 and a two-hundred day moving average price of $111.28. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, equities analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were given a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. This represents a dividend yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.